Pivotal Data on Myeloid Disorders From the 2013 Hematology

Conference

Activity Goals

Myelofibrosis

Newly Identified Biological Pathway May Aid Diagnosis, Treatment of MPNs

Ruxolitinib Escalated Dosing in MF

Characteristics of Patients With MF and Ruxolitinib Resistance

Ruxolitinib Continues to Show Improved Survival in MF

Momelotinib for MF: Long-term Results

BMS-911543 in MF: Phase 1/2a Data

Fedratinib in Patients With Previous Ruxolitinib

Telomerase Inhibitor Imetelstat in MF

Myeloproliferative Neoplasms

Bone Marrow Features May Identify Early Polycythemia Vera

(PV)

History of Thrombosis at Diagnosis of ET

Splanchnic Vein Thrombosis and MPNs

LY2784544 for MF, PV, and ET

AOP2014 for PV: Phase 1/2 Study

AOP2014 for PV: Molecular Responses and Chromosomal Aberrations

Chronic Myeloid Leukemia

ENESTnd Trial Update: Nilotinib (NIL) vs Imatinib (IM)

First Results of the LASOR Trial: Switching From IM to NIL

STIM1 Study Long-term Follow-up

STIM2 Study: Preliminary Results

Immune Surveillance May Contribute to CML Control After TKI Discontinuation

Myelodysplastic Syndromes

Gene Mutation/Deletion Status Predicts Prognosis in

Myelodysplastic Syndromes (MDSs)

IPSS-R Predicts Response to Demethylating Agents (DMAs) in

MDS

IPSS-R Predicts Response to Erythropoietin-Stimulating Agents

(ESAs)

Response to Lenalidomide in Lower-risk MDS Better When Used as First-line Treatment

Combination of Vorinostat + Azacitidine in MDS

Genomic Changes Associated With Smoking

Epoetin Alpha (EPO) Effective in Low-risk MDS

Acute Lymphoblastic Leukemia

CTL019 Cells Efficacious in Pilot Study in Relapsed/Refractory ALL

CTL019 Cells Efficacious for Children With ALL Even After

Allogeneic Stem Cell Transplant (SCT)

Blinatumomab for Children With ALL

Inotuzumab Plus Mini-hyper-CVD for Older Adults With ALL

Pediatric Regimen for Adolescents and Young Adults With ALL: Toxicity Results

Pediatric Regimens for Adolescents and Young Adults With ALL

Acute Myeloid Leukemia

Explanations for Progress in Survival in Core Binding Factor

AML

Dasatinib for Newly Diagnosed AML

Sequential HAM Reduces Hematologic Toxicities in AML

Clofarabine Salvage Therapy May Be Bridge to SCT in AML

Selinexor (KPT-330) for AML: Phase 1 Data

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)